t is consensus that Caucasian patients with coronary artery disease (CAD) should be preferentially treated with a potent statin to lower their low-density lipoprotein cholesterol (LDL-C) level to less than 70 mg/dl based on solid evidence from many randomized clinical trials (RCTs). 1 However, for Asian patients, including Japanese, there is still a lack of concrete evidence for the type of statin and level of LDL-C that should comprise the treatment goals for CAD patients. In fact, although the Japan Atherosclerosis Society launched a new guideline for the diagnosis and prevention of atherosclerotic cardiovascular disease (CVD) in Japanese in April 2012, the recommended LDL-C level for secondary prevention in CAD patients was set lower than 100 mg/dl. One of the main reasons for this decision is that there are not yet results of RCTs for secondary prevention in Japanese CAD patients. In this editorial, the current status of evidence for secondary prevention in Japanese patients, inherent problems and future perspective are noted.
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World-wide, the usual primary endpoint of RCTs is major adverse cardiovascular events (MACE), consisting of cardiovascular death, non-fatal myocardial infarction and stoke, thus comprising a hard endpoint. 1 However, because Japanese patients are followed up more often and more carefully than in other countries, and because they are often treated prophylactically, the rate of MACE may be less than elsewhere. Accordingly, to increase the number of incident case some studies include soft endpoints such as coronary revascularization, congestive heart failure, unstable angina, rehospitalization because of CAD and peripheral arterial disease as primary events (Table) . So, we have to be cautious when comparing Japanese clinical studies with RCTs from other countries. This seems most true when dealing with primary prevention studies such as the MEGA study because the coronary event rate in Japanese, especially Japanese women, is very low. 2 For example, Matsumoto et al 3 followed up "MACE" for 5 years in patients who underwent successful percutaneous coronary intervention (PCI) for acute coronary syndromes or stable angina. They compared cumulative event rates according to the patients' ratio of low-and high-density lipoprotein cholesterol and demonstrated that this ratio is an excellent predictor of CVD. However, their "MACE" included new coronary stenosis and restenosis at the PCI lesion (Table) , and the event rate in 5 years was as high as 33.3%, but CV death and myocardial infarction was only 2.3%. As presented in this issue of the Journal, it is noteworthy in this context that, for the first time in a Japanese secondary prevention study ( Table) , the study by Natsuaki et al counted only a hard endpoint. 4 Recent Japanese secondary prevention studies, including the present one by Natsuaki et al, have demonstrated that statin treatment lowers CV events in CAD patients compared with controls without statin treatment. 4-6 Thus, it is now consensus that a statin should be administered to Japanese CAD patients. In 2010 in the Circulation Journal there was a Pro-Con debate on the extent to which LDL-C should be decreased by statin therapy in Japanese CAD patients. 7, 8 Miyauchi and Daida insisted that "the lower the better" is true, citing their own data on coronary atheroma regression by intensive statin treatment and recommended that Japanese CAD patients' LDL-C levels should be less than 70 mg/dl, similar to that for Caucasians. 7 In contrast, Sakamoto and Ogawa recommended that because of the lack of evidence for LDL-C treatment targets in Japanese "Just make it lower" is enough. The very recent prospective study by Kohro et al demonstrated that intensively lowering LDL-C did not reduce CV risk in Japanese CAD patients as long as LDL-C is less than 100 mg/dl. In line with this notion, the present report by Natsuaki et al concludes that when LDL-C is less than 120 mg/dl, the risk for CV events is comparable even if the achieved LDL-C level is further lowered. As a final note to this issue, we await the results of a large, prospective, multicenter ongoing RCT in Japanese CAD patients (REAL-CAD: Clinical Trials gov. no. NCT01042730).
Sakamoto et al reported that the hydrophilic statin, pravastatin, could be better than other lipophilic statins, based on the results of their MUSASHI-AMI trial, because although pravastatin was less potent in lowering the LDL-C level, it was superior to lipophilic statins at preventing new Q-wave appearance, and reducing cardiovascular events and heart failure. 5 However, Natsuaki et al report that in the strong statin group, approximately 70% of which was treated with lipophilic ator-LDL-C Level for Secondary Prevention of CAD vastatin, there was less MACE than in the mild statin group, approximately 70% of which was treated with pravastatin. 4 Pravastatin is only a hydrophilic stain and it is reviewed that it ameliorates insulin sensitivity, HbA1c and increases adiponectin, resulting in favor of preventing the progression of atherosclerosis compared with other lipophilic statins and the semi-hydrophilic rosvastatin. 10 Of note, a recent prospective head-to-head clinical trial in which the effects of aggressive LDL-C lowering with rosuvastatin and mild LDL-C lowering with pravastatin were compared in terms of regression/progression of the intima-media thickness (IMT) of the carotid artery revealed that the former regressed and the latter progressed IMT in 1 year, while the former significantly worsened HbA1c compared with the latter. 11 Thus, although pravastatin is better than strong statins with regard to metabolic parameters, the greater LDL lowering by strong statins may override this effect. 12 This issue will be answered by an ongoing prospective study "the ALPS-AMI" where the outcome for pravastatin and atorvastatin is being compared in a headto-head manner after CAD patients' LDL-C was lowered to less than 100 mg/dl by both treatments. 13 In the present study by Natsuaki et al, the high-density lipoprotein cholesterol (HDL-C) level of patients with LDL-C of 80-100 mg/dl was slightly higher than in the other groups. This may have lowered the incidence of MACE in this group, resulting in a negation of the difference between that of patients with LDL-C 100-120 mg/dl. Because HDL-C has been reported to have a great effect on the occurrence of CV events, 14 and because HDL-C was not included as a potential independent variable selected for multivariate analysis, further analyses that include HDL-C are mandatory.
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